CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - Generic Drug Details

What are the generic sources for candesartan cilexetil; hydrochlorothiazide and what is the scope of freedom to operate?

Candesartan cilexetil; hydrochlorothiazide is the generic ingredient in two branded drugs marketed by Ani Pharms, Apotex Inc, Macleods Pharms Ltd, Pharmobedient, Prinston Inc, Senores Pharms, and Zydus Lifesciences, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	6
DailyMed Link:	CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE at DailyMed

Recent Clinical Trials for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
Takeda	Phase 4
Takeda

See all CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE clinical trials

Generic filers with tentative approvals for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Applicant	Application No.	Strength	Dosage Form
		32MG; 12.5MG	TABLET; ORAL
		16MG; 12.5MG	TABLET; ORAL
		32MG; 25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATACAND HCT	Tablets	candesartan cilexetil; hydrochlorothiazide	32 mg/25 mg	021093	1	2009-03-06
ATACAND HCT	Tablets	candesartan cilexetil; hydrochlorothiazide	16 mg/12.5 mg and 32 mg/12.5 mg	021093	1	2008-06-25

US Patents and Regulatory Information for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Macleods Pharms Ltd	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	204100-001	Feb 27, 2015	AB	RX	No	No
Senores Pharms	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	202965-003	Jun 3, 2013	AB	RX	No	No
Prinston Inc	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	207455-003	Apr 11, 2018	AB	RX	No	No

Expired US Patents for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093-003	May 16, 2008
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093-002	Sep 5, 2000
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093-001	Sep 5, 2000

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Candesartan Cilexetil with Hydrochlorothiazide?

Candesartan cilexetil combined with hydrochlorothiazide (HCTZ) is a fixed-dose combination used primarily to treat hypertension and heart failure. The combination leverages candesartan's angiotensin II receptor blockade with HCTZ's diuretic properties, offering convenience and improved adherence compared to monotherapy.

Market Drivers

• Growing Hypertension Prevalence: Estimated at 1.3 billion globally, rising populations and aging demographics increase demand for antihypertensive therapies. The World Health Organization forecasts continued growth in hypertension cases, especially in Asia-Pacific and Africa, where treatment rates remain low.

• Guideline-Driven Prescribing: Clinical guidelines such as the American College of Cardiology/American Heart Association (ACC/AHA) recommend combination therapy for stage 2 hypertension. The preference for fixed-dose combinations (FDCs) to improve adherence boosts demand for products like candesartan/HCTZ.

• Patent Expiry and Generics: The original patent for candesartan expired in 2017 in the US, leading to a surge in generic versions. This transition has decreased prices and increased accessibility, expanding market volume.

• Regulatory Approvals: Regulatory agency approvals in emerging markets facilitate market penetration, especially where generic options are more affordable.

Market Challenges

• Pricing and Reimbursement Pressures: As several generics enter the market, price competition intensifies. Reimbursement policies in developed markets often favor lower-cost generics, squeezing margins for branded products.

• Market Saturation: Hypertensive patients often remain on multiple medications. Transition to combination drugs depends on physician prescribing habits and patient compliance, which vary geographically.

• Therapeutic Competition: Other combination drugs, such as amlodipine with HCTZ or lisinopril with HCTZ, compete on efficacy, safety, and cost.

• Side Effect Profile: The combination's tolerability influences prescribing. HCTZ can cause electrolyte imbalance, limiting its use in some populations.

Geographic Market Insights

Region	Market Size (USD millions, 2022)	Growth Rate (CAGR 2022-2027)	Key Factors
North America	450	3%	High hypertension prevalence; strong generic competition
Europe	370	2.5%	Reimbursement constraints; aging population
Asia-Pacific	600	8%	Rapid urbanization; increasing awareness
Latin America	150	4%	Growing healthcare access; generics availability

What Is the Financial Trajectory for Candesartan Cilexetil with Hydrochlorothiazide?

Revenue Projections

The global market for antihypertensives, including combination drugs, is expected to reach USD 30 billion by 2027, growing at a compound annual growth rate (CAGR) of 3.5%. Candesartan/HCTZ products, as part of this category, are projected to account for approximately USD 500 million in sales in 2023.

Analysts forecast that:

• Generic Transition Effect: After patent expiration, the introduction of generics caused a decline in average selling prices (ASP). In 2017-2019, ASPs for branded candesartan/HCTZ products dropped by approximately 25%, with volume growth partially offsetting this decline.

• Market Rebound in Emerging Markets: Rising healthcare infrastructure and increased access lead to higher prescription volumes, especially where affordability improves owing to generics.

• Manufacturing and Pricing Strategies: Companies that hold patents or exclusive formulations can command premium prices, but only in markets with limited generic competition.

Cost and Profitability Analysis

• Development Costs: New formulations or combinations typically require preclinical trials, bioequivalence studies, and regulatory filings, with costs ranging from USD 50 million to USD 200 million.

• Manufacturing: The production cost for a 30-tablet pack averages USD 0.10-0.20 per unit for generics. Branded products may include higher margins due to branding and marketing expenses.

• Pricing Trends: Average retail prices for branded Candesartan/HCTZ range between USD 60-80 per month in the US, compared to USD 20-40 for generics.

• Market Entry Barriers: Patent litigation, regulatory approval timelines, and access restrictions influence profitability.

Investment Outlook

• Major Market Players: Companies such as Merck, Teva, Mylan (now part of Viatris), and local generics producers dominate the segment. Strategic alliances and patent litigations shape market share.

• Emerging Opportunities: Developing markets present growth due to rising hypertension prevalence and lower regulatory hurdles. Digital health initiatives and adherence programs promote sustained use.

What Are the Strategic Considerations?

• Entering or expanding in markets where patent exclusivity still exists offers higher margins.

• Investing in formulations that improve bioavailability or boundary-pushing combination ratios may sustain premium pricing.

• Licensing agreements with local manufacturers can accelerate market entry in emerging regions.

• Focusing on reducing manufacturing costs can improve competitiveness in price-sensitive markets.

Final Observations

Market dynamics favor increased accessibility and volume for candesartan cilexetil combined with hydrochlorothiazide, especially through generic proliferation. Financial growth depends on navigating patent landscapes, pricing pressures, and regional healthcare policies.

---

Key Takeaways

• The global antihypertensive market is expanding, with fixed-dose combinations like candesartan/HCTZ integral to prescriptions.
• Price competition post-patent expiry significantly affects margins; generics dominate in many markets.
• Emerging markets show higher growth potential driven by demographic shifts and improved healthcare access.
• Revenue projections for the segment suggest steady growth, but margins are increasingly commoditized.
• Strategic innovations and regional expansion are key to maximizing profitability.

---

FAQs

1. How does patent expiration affect sales of candesartan/HCTZ?
Patent expiration leads to generic entries, reducing prices and market exclusivity, causing sales volume to rise but profit margins to decline, unless branded products maintain differentiation.

2. Which regions present the highest growth opportunities?
Asia-Pacific and Latin America offer high growth due to rising hypertension rates and improving healthcare infrastructure.

3. What are the main factors influencing profitability in this segment?
Pricing strategies, patent status, manufacturing costs, regional reimbursement policies, and competitive product offerings.

4. Are there specific regulatory hurdles for launching generics?
Yes, approval depends on demonstrating bioequivalence, navigability of national registration processes, and patent litigation in certain markets.

5. What trends could shift the market landscape in the next five years?
Development of novel formulations, combination therapies with improved safety profiles, digital adherence tools, and market consolidation among generic manufacturers.

---

References

1. World Health Organization. Hypertension Fact Sheet. 2022.
2. MarketsandMarkets. Antihypertensive Drugs Market. 2022.
3. U.S. FDA. Approved Drug Products. 2023.
4. IMS Health. Global Prescriptions Trends. 2022.
5. European Medicines Agency. Regulatory Guidelines for Generics. 2022.